Teligent, a New Jersey-based specialty generic pharmaceutical company, announced that it has received approvals of the company's abbreviated new drug applications (ANDAs) from the U.S. Food and Drug Administration (FDA) for both Triamcinolone Acetonide Lotion USP, 0.1% and Triamcinolone Acetonide Lotion USP, 0.025%. The FDA has now approved seven ANDAs from the Company's internally developed pipeline of topical generic pharmaceutical products.
Based on IMS Health data from May 2016, the total addressable market for these two products is approximately $6.8 million.
"We are excited to add these two new products to our growing portfolio of topical prescription medicines," commented Jason Grenfell-Gardner, President and CEO of the Company. "We have now received six approvals from the FDA this year, including an earlier approval of a partnered submission. Our team is committed to bringing these products to market this quarter.''